TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Purple Biotech ( (PPBT) ) just unveiled an update.
On November 14, 2025, Purple Biotech announced its third-quarter financial results and business update. The company highlighted the development of its CAPTN-3 platform, including the initiation of a second tri-specific antibody targeting TROP2 and achieving a manufacturing milestone for IM1240. With a cash position of $10.5 million as of September 30, 2025, Purple Biotech anticipates a cash runway into the first half of 2027, supporting significant milestones. The company plans to conduct toxicology studies and initiate a Phase 1 study for IM1240 in 2026. Financially, Purple Biotech reported a decrease in research and development expenses and operating loss compared to the previous year, primarily due to reduced costs associated with the CM24 Phase 2 study.
The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.
Purple Biotech’s overall stock score reflects significant financial challenges and unattractive valuation metrics. The absence of revenue and ongoing losses weigh heavily on financial performance. Technical indicators are mixed, with some potential downside risks. The lack of profitability and dividends further contribute to a low valuation score.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage company based in Rehovot, Israel, focused on developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance. The company’s oncology pipeline includes CAPTN-3, CM24, and NT219, with CAPTN-3 being a preclinical platform of conditionally activated tri-specific antibodies designed to engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment.
Average Trading Volume: 7,846,812
Technical Sentiment Signal: Sell
Current Market Cap: $7.5M
See more data about PPBT stock on TipRanks’ Stock Analysis page.